Revenue: As of FY2026 Q1, the actual value is USD 1.458 M, missing the estimate of USD 4.254 M.EPS: As of FY2026 Q1, the actual value is USD -1.28, missing the estimate of USD -1.2572.EBIT: As of FY2026 Q1, the actual value is USD -121.54 M.<h3>Segment Revenue</h3><ul><li>Collaboration Revenue: CRISPR Therapeutics AG recognized $1,000 thousand in collaboration revenue for the three months ended March 31, 2026, an increase of $1,000 thousand compared to $0 for the same period in 2025 .</li><li>Grant Revenue: Grant revenue was $458 thousand for the three months ended March 31, 2026, marking a decrease of $407 thousand from $865 thousand in the prior year period .</li><li>Total Revenue: Total revenue increased by $593 thousand, from $865 thousand in the three months ended March 31, 2025, to $1,458 thousand in the three months ended March 31, 2026 .</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss: CRISPR Therapeutics AG reported a net loss of - $122,931 thousand for the three months ended March 31, 2026, an improvement from a net loss of - $135,996 thousand for the same period in 2025, reflecting a decrease of $13,065 thousand .</li><li>Research and Development (R&amp;D) Expenses: R&amp;D expenses decreased by $3,910 thousand, from $72,484 thousand for the three months ended March 31, 2025, to $68,574 thousand for the three months ended March 31, 2026, primarily due to a reduction in employee-related costs, partially offset by an increase in external R&amp;D expenses .</li><li>General and Administrative (G&amp;A) Expenses: G&amp;A expenses decreased by $2,113 thousand, from $19,296 thousand for the three months ended March 31, 2025, to $17,183 thousand for the three months ended March 31, 2026, mainly due to lower employee-related costs .</li><li>Collaboration Expense, Net: Collaboration expense, net, decreased by $11,560 thousand, from $57,509 thousand for the three months ended March 31, 2025, to $45,949 thousand for the three months ended March 31, 2026, primarily due to an increase in CRISPR Therapeutics AG’s share of CASGEVY revenue .</li><li>Other Income, Net: Other income, net, decreased by $5,381 thousand, from $13,537 thousand for the three months ended March 31, 2025, to $8,156 thousand for the three months ended March 31, 2026, mainly due to the change in fair value of corporate equity securities .</li><li>Loss from Operations: Loss from operations improved by $18,176 thousand, from - $148,424 thousand in Q1 2025 to - $130,248 thousand in Q1 2026 .</li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities increased by $54,950 thousand, from - $53,947 thousand for the three months ended March 31, 2025, to - $108,897 thousand for the three months ended March 31, 2026 . This increase was primarily driven by a $70.3 million overall decrease in net changes of operating assets and liabilities, partially offset by a decrease in net loss .</li><li>Net Cash Used in Investing Activities: Net cash used in investing activities increased by $390,988 thousand, from - $19,755 thousand for the three months ended March 31, 2025, to - $410,743 thousand for the three months ended March 31, 2026, primarily due to a net increase in purchases of marketable securities .</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities significantly increased by $581,320 thousand, from $10,588 thousand for the three months ended March 31, 2025, to $591,908 thousand for the three months ended March 31, 2026 . This was primarily driven by $585.4 million in net proceeds from the issuance of Convertible Senior Notes in March 2026 .</li><li>Cash, Cash Equivalents, and Marketable Securities: As of March 31, 2026, CRISPR Therapeutics AG had $2,441.8 million in cash, cash equivalents, and marketable securities, with approximately $305.2 million held outside the United States .</li></ul><h4>Unique Metrics</h4><ul><li>Convertible Senior Notes: In March 2026, CRISPR Therapeutics AG issued $600.0 million aggregate principal amount of Convertible Senior Notes due 2031, resulting in net proceeds of approximately $585.4 million after deducting offering expenses .</li><li>Deferred Costs (CASGEVY program): As of March 31, 2026, deferred costs under the A&amp;R Vertex JDCA for the CASGEVY program totaled $221.8 million, which are payable to Vertex as an offset against future profitability of the CASGEVY program .</li></ul><h4>Future Outlook and Strategy</h4><ul><li>Core Business Focus: CRISPR Therapeutics AG aims to create transformative gene-based medicines, focusing on developing CRISPR-based therapeutics across hemoglobinopathies (CASGEVY), in vivo approaches (CTX310, CTX340, CTX321, CTX460), CAR-T (zugocabtagene geleucel), and regenerative medicine (CTX213) . The company is also advancing next-generation editing modalities like SyNTase editing and technologies for whole gene correction and all-RNA systems .</li><li>Financial Outlook: CRISPR Therapeutics AG expects its existing cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures for at least the next 24 months, not accounting for additional proceeds from license agreements or future capital raising . The company anticipates continued losses for the foreseeable future and expects expenses to increase due to ongoing R&amp;D, new programs, clinical trials, business development, regulatory approvals, and infrastructure expansion .</li></ul>

CRISPR Therap | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 1.458 M